

Wild-Type Phages for CRE Infections

Research Team

- Researcher: Kotaro Kiga
- Affiliation: Department of Drug Development
- Team: Shinjiro Ojima et al.
- Target: Carbapenem-resistant Enterobacterales (CRE) infections
- Development stage: Applied research (lead candidate selection nearly complete)

Research Concept & Technology

- Development candidate: Wild-type phages
- Identify wild-type phages active against clinical CRE isolates and advance them toward therapeutic use
- Conduct translational studies to finalize lead phage selection
- Efficacy demonstrated in a mouse systemic infection model
- Safety evaluated in rats

Background & Unmet Need

- CRE infections have limited treatment options and pose a major infection-control challenge in healthcare settings
- Diversity in bacterial species and patient characteristics calls for isolate-specific approaches
- New therapies that complement antibiotics are urgently needed for severe infections

Project Overview



Development Plan

- Expand the CRE isolate panel and phage library
- Define quality, safety, and dosing strategies for lead phages (Co-development partners sought)